CEO Remarks

We believe that it is urgent to secure an alternative technology to the current blood transfusion method that heavily relies on blood donation. To strengthen blood supply capabilities in response to deep blood shortages and national disasters, we need to overcome rare blood supply limitations and provide safe blood products without adverse reactions.

We continuously utilize cutting-edge gene editing & stem cell technologies to generate universal cRBC that can be transfused to anyone safely. Therefore, we can secure a cultured red blood cell production technology for universal blood transfusion, even for rare blood patients, and for therapeutic purpose. In addition, by promoting the development of innovative cell gene technology (CGT), it is expected to enter the fast-growing advanced regenerative bio field and creating new bio-health industries.

We have strong interests not only in the development of cultured human blood, but also in the development of culture blood for companion animals (dogs and cats). Nowadays demand for canine and feline blood products has significantly increased over the past two decades, due to advances in veterinary medicine and medical care. It is now common for animals to receive blood transfusions for the treatment of several serious diseases.

In conclusion, RedGene will continue to pursue producing cultured red blood cells for human & companion animals for clinical needs by utilizing competitive research infrastructures, excellent networks, and cutting-edge gene editing & stem cell technologies. We confidently promise that RedGene will successfully achieve the production of cultured artificial red blood cells that show excellent quality, safety and good affordability.



Go RedGene! Thanks.

CEO Kaapjoo Park, PhD